Sponsored Links


Displaying crizotinib PowerPoint Presentations

PowerPoint Presentation PPT

Presentation Summary : ... JTO 2010 Rapid and dramatic tumor response in ALK+ NSCLC to crizotinib Best Percent Change from Baseline in Target Lesions % Decrease or increase from ...

Source : http://l39gg632kcb0ewpfj-sites-default-files.s3.amazonaws.com/0830%20Camidge%20v2.ppt

PowerPoint Presentation PPT

Presentation Summary : Break Apart FISH. 2p23. ALK. Dual Color, ... Acquired Resistance to Crizotinib in ALK FISH+ . Multiple mutations in . ALK. tyrosine kinase domain. New oncogenic ...

Source : http://www.scientificorganizingservice.com/public/M.pptx

ALK in lung cancer: Past, present, and future PPT

Presentation Summary : Mechanisms of resistance to crizotinib in ALK-positive NSCLC. Camidge, D. R. Nat Rev ClinOncol. 2012 Apr 3. What Can We Do? Summary of Crizotinib Resistance.

Source : http://cisc.twbbs.org/media/slide/3147.pptx

The first 12 months of UK diagnostic services for EGFR gene ... PPT

Presentation Summary : EGFR gene mutation testing ... Crizotinib FISH (IHC, PCR) Crizotinib and EML4- ALK fusions ~4.5% adenocarcinoma patients Dramatic response to therapy ...

Source : http://www.rcpath.org/Resources/MSPowerpoint/Dr%20R%20Butler.ppt

For 24 hour support call +44 151 259 62 62 PPT

Presentation Summary : ... Personalized Medicine Shaw A T and Engelman J A JCO 2013;31:1105-1111 (A) Before crizotinib; (B) after 7 weeks of crizotinib.

Source : http://cancer.dartmouth.edu/lung_thoracic/documents/C_Tsongalis.ppt

Therapeutic Decision Making in Advanced NSCLC: A 2012 Perspective PPT

Presentation Summary : Therapeutic Decision Making in Advanced NSCLC: A 2012 Perspective David R. Gandara, MD ... You can see the choice here is clearly the ALK inhibitor crizotinib.

Source : http://s3.amazonaws.com/AdvancedNSCLC2012/CCO_Advanced_NSCLC_Decisions_2012_Slides.ppt

Slide - Maine Dartmouth Family Medicine Residency PPT

Presentation Summary : Slide 1 Author: Your User Name ... the US FDA gave approval of crizotinib by for the treatment of ALK-rearranged lung cancer PowerPoint Presentation ...

Source : http://www.mainedartmouth.org/PowerPointSlides/LIU,%20Ed.ppt

Breakthrough Therapies, Jeff Allen, PhD (June 2013) - Friends ... PPT

Presentation Summary : Breakthrough Therapies Jeff Allen, PhD ... Phase 1 – 80%RR in patients who progressed following crizotinib Note: Substantial improvement over SoC; ...

Source : http://www.focr.org/sites/default/files/DIA%20Breakthrough%20Therapies%20JALLEN%206%2017%2013.ppt

PowerPoint Presentation PPT

Presentation Summary : KVM Huber et al. Nature 000, 1-6 (2014) doi:10.1038/nature13194 Specificity and MTH1 co-crystal structure of (S)-crizotinib. Title: PowerPoint Presentation

Source : http://www.nature.com/nature/journal/v508/n7495/slides/nature13194-pf3.ppt

Slide 1 PPT

Presentation Summary : Targeting ALK Crizotinib Novel Agents Pralatrexate Case 3 AITL Case 3 Presentation, Biopsy, PET/CT Scan A 70-year-old women presented with a macular rash, ...

Source : http://img.medscape.com/images/771/156/771156_slides.ppt

Molecular Management of Advanced NSCLC PPT

Presentation Summary : Crizotinib – active in ALK/ROS1 translocated patients, ? met amplification/mutated. BRAF mutations – vemurafenib, dabrafenib. Studies ongoing with specifically ...

Source : http://elcon.imedex.com/ELC/2013/6699/1000_Socinski.pptx

Oncology Connection: Contemporary Strategies for the ... PPT

Presentation Summary : Treatment 80 60- 40 20 0 ORR, % Crizotinib (n = 173b) Chemotherapy (n = 174b) 19.5 _ | | _ _ Treatment 80 60- 40 20 0 ORR, % Crizotinib (n = 172C) Pemetrexed ...

Source : http://www.med-iq.com/files/noncme/material/ppts/NSCLC.ppt

Personalised Cancer Medicine - rh-kollokvier.dk Website + Hjem PPT

Presentation Summary : Personalised Cancer Medicine in Phase 1 Cancer Research at Rigshospitalet Ulrik Lassen ... and crizotinib was FDA-approved in 2011 UL/2012 Mab og TKI Kwak EL et al, ...

Source : http://www.rh-kollokvier.dk/Portals/0/Dr.%20Ulrik%20Lassen%20-%20RH.ppt

Diapositiva 1 PPT

Presentation Summary : Patient was started on crizotinib 250 mg x 2. Case Report . 46-ys-old . light ex-smoker. woman. August 2012: Start crizotinib. After 1 month of crizotinib. Almost ...

Source : http://www.perunavitacomeprima.org/principale/convegno2013/documenti/CRINO.pptx

PowerPoint Presentation PPT

Presentation Summary : ... http://www.sanger.ac.uk/genetics/CGP/cosmic/ Text Erlotinib (2004) Crizotinib (2011) Vandetinib Vemurafinib Resistance to Erlotinib? Genome Res. 2012 Nov;22 ...

Source : http://s3.amazonaws.com/ascpcdn/static/adasp/assets/2013+PPTs/Eberhard+ADASP+talk+02Mar2013.ppt

PowerPoint Presentation PPT

Presentation Summary : On behalf of the Lung Cancer Mutation Consortium Investigators. ... Some progressed in crizotinib and are now considered for other clinical trials .

Source : http://www.oncoletter.ch/fileupload/MariellaGarcia.pptx


Presentation Summary : Esophagogastric Cancer: CMET as a Novel Target David H. Ilson, M.D., Ph.D. ... VEGFr2) Tivantinib Crizotinib Resistance to MET Activation Esophagogastric Cancer: ...

Source : http://imedex.com/gi-malignancies-debate-conference/archive/2014/assets/presentations/Friday/1630%20Ilson_cMET.ppt

Sponsored Links

Report a violation: If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com